A relatively new therapy for treatment of liver cancer in the form of selective internal (liver targeted) radiation treatment is now available at University of Washington. It involves the delivery of tiny radiation particles (Yttrium-90 or commonly called Y90) directly into the tumors within the liver through the blood vessels supplying the tumor – with the potential to reduce systemic toxicities. Dr. Gaurav K Goswami of Interventional Radiology and Dr. Joseph Rajendran of Nuclear Medicine along with their colleagues have worked together to establish this treatment, here at UW. It is one of the many treatments available at UW for patients with liver cancer. In the words of  the former UW IR faculty,  Dr. Guarav Goswami, “Every patient with liver cancer is different and their treatments have to be tailored according to the requirements of the patient, the biologic behavior of their tumors and the ability to tolerate such treatments. Radioembolization with Yttrium-90 adds another weapon to the wide arsenal of treatments available at UW for patients with liver cancer”. This treatment is FDA approved for both primary and secondary liver tumors and in selected patients has shown promising initial results. Please click the link below to view an article about Dr. Goswami's liver cancer treatment - Y-ttrium 90: